These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34931674)

  • 41. Prognostic Factors and Clinical Characteristics of Chronic Hepatitis B with or without Nucleos(t)ide Analogues Therapy: A Retrospective Study.
    Li M; Li T; Li K; Lan H; Hao X; Liu Y; Zhou C
    Ann Clin Lab Sci; 2022 Jan; 52(1):133-139. PubMed ID: 35181627
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
    Yip TC; Wong GL; Wong VW; Tse YK; Liang LY; Hui VW; Lee HW; Lui GC; Chan HL
    J Hepatol; 2020 May; 72(5):847-854. PubMed ID: 31857194
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study.
    Yin J; Wang J; Pu R; Xin H; Li Z; Han X; Ding Y; Du Y; Liu W; Deng Y; Ji X; Wu M; Yu M; Zhang H; Wang H; Thompson TC; Ni W; Cao G
    Cancer Prev Res (Phila); 2015 Oct; 8(10):978-88. PubMed ID: 26290395
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-world study on clinical outcomes of nucleos(t)ide analogues antiviral therapy in patients with chronic hepatitis B.
    Sun Y; Zhang Y; Xu Y; Shu M; Bonroy K; Qiu H; Cai W
    Epidemiol Infect; 2019 Jan; 147():e193. PubMed ID: 31364558
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort.
    Bockmann JH; Grube M; Hamed V; von Felden J; Landahl J; Wehmeyer M; Giersch K; Hall MT; Murray JM; Dandri M; Lüth S; Lohse AW; Lütgehetmann M; Schulze Zur Wiesch J
    BMC Gastroenterol; 2020 Jan; 20(1):24. PubMed ID: 32000689
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
    Kim CH; Um SH; Seo YS; Jung JY; Kim JD; Yim HJ; Keum B; Kim YS; Jeen YT; Lee HS; Chun HJ; Kim CD; Ryu HS
    J Gastroenterol Hepatol; 2012 Oct; 27(10):1589-95. PubMed ID: 22554121
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Kinetics of serum O-glycosylated M-hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patients.
    Okumura T; Joshita S; Iwadare T; Wakabayashi SI; Kobayashi H; Yamashita Y; Sugiura A; Kimura T; Umemura T
    J Viral Hepat; 2023 Sep; 30(9):731-739. PubMed ID: 37363934
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Risk factors for the development of liver cancer in patients with hepatitis B-related liver cirrhosis treated with long-term nucleos(t)ide analogues].
    Zang WW; Su MH; Ling XZ; Wang RM; Cao BC; Wu YL; Deng DL; Wei HL; Liang XS; Jiang JN
    Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):679-685. PubMed ID: 32911907
    [No Abstract]   [Full Text] [Related]  

  • 49. [Timing and selection of antiviral therapy with nucleos(t)ide analogues for prevention of hepatitis B virus-related HCC].
    Han C; Lai PP; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):827-830. PubMed ID: 31941235
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
    Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
    J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
    Yip TC; Lai JC; Wong GL
    J Gastroenterol; 2020 Nov; 55(11):1023-1036. PubMed ID: 32974760
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
    Lampertico P; Invernizzi F; Viganò M; Loglio A; Mangia G; Facchetti F; Primignani M; Jovani M; Iavarone M; Fraquelli M; Casazza G; de Franchis R; Colombo M
    J Hepatol; 2015 Nov; 63(5):1118-25. PubMed ID: 26100495
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
    Kim MA; Kim SU; Sinn DH; Jang JW; Lim YS; Ahn SH; Shim JJ; Seo YS; Baek YH; Kim SG; Kim YS; Kim JH; Choe WH; Yim HJ; Lee HW; Kwon JH; Lee SW; Jang JY; Kim HY; Park Y; Kim GA; Yang H; Lee HA; Koh M; Lee YS; Kim M; Chang Y; Kim YJ; Yoon JH; Zoulim F; Lee JH
    Gut; 2020 Dec; 69(12):2214-2222. PubMed ID: 32209606
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study.
    Yang DH; Wang WP; Zhang Q; Pan HY; Huang YC; Zhang JJ
    World J Gastroenterol; 2021 May; 27(17):2025-2038. PubMed ID: 34007137
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study.
    Wu CY; Lin JT; Ho HJ; Su CW; Lee TY; Wang SY; Wu C; Wu JC
    Gastroenterology; 2014 Jul; 147(1):143-151.e5. PubMed ID: 24704525
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma.
    Wu JW; Kao JH; Tseng TC
    Clin Mol Hepatol; 2021 Oct; 27(4):524-534. PubMed ID: 33618507
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load.
    Tseng TC; Liu CJ; Hsu CY; Hong CM; Su TH; Yang WT; Chen CL; Yang HC; Huang YT; Fang-Tzu Kuo S; Liu CH; Chen PJ; Chen DS; Kao JH
    Gastroenterology; 2019 Dec; 157(6):1518-1529.e3. PubMed ID: 31470004
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics.
    Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
    J Hepatol; 2016 Jul; 65(1):48-56. PubMed ID: 27034253
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.
    Chi H; Li Z; Hansen BE; Yu T; Zhang X; Sun J; Hou J; Janssen HLA; Peng J
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):182-191.e1. PubMed ID: 29902645
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
    Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
    J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.